The Centers for Medicare and Medicaid Services issued guidance today noting that Insulet‘s (NSDQ:PODD) Omnipod tubeless insulin delivery device can be covered by the Medicare Part D prescription drug program.
The Billerica, Mass.-based company estimated that its latest reimbursement win extends access to the Omnipod system to 450,000 people with Type I diabetes across the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet lands Medicare Part D coverage for Omnipod insulin delivery system appeared first on MassDevice.
from MassDevice http://ift.tt/2ADEBDg
Cap comentari:
Publica un comentari a l'entrada